FDA advisory committee convenes to evaluate Capricor Therapeutics' Duchenne muscular dystrophy treatment

An FDA advisory committee is reviewing the efficacy and safety data for Capricor Therapeutics' Duchenne muscular dystrophy drug, a process marked by prior regulatory contention. The committee's recommendation will significantly influence the FDA's final approval decision, which remains uncertain due to debate over clinical trial endpoints.